Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. \DE\LFCR · Entity 6447 | Director | June 04, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LIFECORE BIOMEDICAL, INC. \DE\
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,967 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 25,907 · Balance 69,967 F1: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2: Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026). |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
F2: Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 5, 2026 20:45 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | GrantCommon Stock | 25,907 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002034858-26-000002 · wk-form4_1780692301.xml · nonDerivative · entry 1 Johnson Paul Harold · CIK 0002034858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,967 F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · price: Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026). Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 20:45 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | GrantCommon Stock | 19,506 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001005286-25-000092 · wk-form4_1752785118.xml · nonDerivative · entry 1 Johnson Paul Harold · CIK 0002034858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,060 F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · price: Vests on the earlier of the one year anniversary of the date hereof or the date of the annual meeting of stockholders of the Company first held in calendar year 2026 (provided such date is no less than 50 weeks from the date hereof). Read SEC document |
| August 19, 2024 Filed Aug 22, 2024 19:00 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | GrantCommon Stock | 24,554 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-038196 · wk-form4_1724353252.xml · nonDerivative · entry 1 Johnson Paul Harold · CIK 0002034858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,554 F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · price: Vests on earlier of July 8, 2025 or the date of the annual meeting of stockholders of the Company first held in calendar year 2025 (provided such date is no less than 50 weeks from July 8, 2024). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.